{"id":2859,"date":"2024-09-25T17:14:24","date_gmt":"2024-09-25T17:14:24","guid":{"rendered":"https:\/\/horizon.peachpuff-wolverine-566518.hostingersite.com\/?p=2859"},"modified":"2024-09-26T16:01:19","modified_gmt":"2024-09-26T16:01:19","slug":"european-countries-come-together-to-improve-outcomes-for-young-cancer-patients","status":"publish","type":"post","link":"https:\/\/scienceblog.com\/horizon\/2859\/european-countries-come-together-to-improve-outcomes-for-young-cancer-patients\/","title":{"rendered":"European countries come together to improve outcomes for young cancer patients"},"content":{"rendered":"

EU-funded researchers are working together to improve survival rates and quality of life for children with cancer and reduce inequalities between countries.<\/p>\n

By<\/em> Helen Massy-Beresford<\/p>\n

Dealing with cancer in children is hard enough. Knowing that there are huge disparities in survival rates between higher- and lower-income countries in Europe makes it even worse. But EU-funded researchers are working to address this.<\/p>\n

Dr Jelena Rascon, a paediatric cancer specialist at the\u00a0Vilnius University Hospital Santaros Klinikos (VULSK) in Lithuania, places great importance on the benefits of international cooperation when dealing with cancer \u2013 particularly when it comes to children.<\/p>\n

Increasing the odds<\/strong><\/p>\n

\u201cThere are still inequalities across European countries in terms of childhood cancer survival rates,\u201d said Rascon, who led a three-year EU-funded research initiative called\u00a0TREL<\/a> that began in 2021 and concluded in December 2023. The researchers aimed to improve childhood cancer treatment through greater cooperation between European countries.<\/p>\n

Thanks to funding from the EU, Dr Rascon and her colleagues were able to work closely with partners in\u00a0Austria, Belgium, Denmark, France, Germany, Italy and the Netherlands to reduce persisting disparities and improve survival rates across Europe for children with certain types of cancer.<\/p>\n

This was done through twinning, a concept that allows specialists to network and cooperate more easily with colleagues in other countries where research in a specific area is deemed to be more advanced.<\/p>\n

The TREL team focused on the treatment of\u00a0solid cancerous tumours\u00a0in children and, more specifically, on brain tumours, neuroblastoma and renal tumours.<\/p>\n

Brain tumours are among the most common types of childhood cancers, along with leukaemia and lymphoma. Although childhood cancers are very rare and have a high overall survival rate, they remain the first cause of death from disease in children and adolescents, with an estimated\u00a02\u00a0000<\/a> deaths every year in Europe.<\/p>\n

To help increase the odds of survival, the children taking part in the study had access to personalised treatment plans and follow-ups agreed collectively by the research team.<\/p>\n

In some cases, doctors were able to work with geneticists and bioinformatics specialists from institutions in other European countries \u2013 with considerable positive impact for their young patients and their families.<\/p>\n

Improving survival\u00a0<\/strong><\/p>\n

In the EU, an estimated 14\u00a0000 cases of childhood cancers are recorded every year, according to the European Cancer Inequalities Registry<\/a>.<\/p>\n

The registry puts survival rates at between 73% in Bulgaria and 74% in Lithuania, to 86% in Denmark and 85% in Austria. To put it more simply, for every 100 children with cancer, 12 more will survive in Denmark than in Lithuania.<\/p>\n

The good news is that the prognosis for children with cancer is improving in Lithuania. According to Rascon, the increase in cross-border exchanges organised as part of the TREL cooperation has been an important part of that.<\/p>\n

The TREL researchers\u2019 objectives align well with\u00a0Europe\u2019s Beating Cancer Plan<\/a>, especially its \u2018Helping Children with Cancer\u2019 initiative, as well as the\u00a0EU Cancer Mission\u2019s<\/a>\u00a0science-based approach toward reducing cancer burden and inequalities across the EU.<\/p>\n

International solidarity for better care<\/strong><\/p>\n

Dr Goda Vaitkevi\u010dien\u0117, a colleague of Rascon\u2019s and a paediatric haematologist at\u00a0VULSK, also acknowledges the importance of international solidarity in improving the health outcomes for children everywhere.<\/p>\n

Vaitkevi\u010dien\u0117 worked on two pan-European studies of treatment protocols for children and adolescents with acute lymphoblastic leukaemia (ALL) called NOPHO ALL2008 and\u00a0ALLtogether<\/a>.<\/p>\n

These aimed to improve childhood leukaemia survival rates through clinical trials that, like TREL, included the sharing of data, treatment plans and information between doctors in different European countries.<\/p>\n

International cooperation is particularly important in a field like paediatric cancer, said\u00a0Vaitkevi\u010dien\u0117. She pointed out that as these cancers are extremely rare, it is difficult to have a sufficient number of patients to conduct effective studies and compare protocols within the borders of just one or several small countries.<\/p>\n

For Rascon, the work carried out by the TREL team brought increased knowledge, better access to innovations and better access to international collaborative research.<\/p>\n

\u201cWhen you\u2019re in a research group, you can provide much better care to your patients, more innovative, more tailored. In paediatric oncology, research is a platform to provide better care,\u201d she said.<\/p>\n

Future outlook<\/strong><\/p>\n

Thanks to the work carried out by the TREL researchers, the team has been able to secure funding for a new project, SCARLET<\/a>, set to begin in October 2024, allowing it to carry on making improvements.<\/p>\n

The advantages go both ways, with data related to the Lithuanian children involved in the clinical trials now feeding into a Europe-wide study that can improve overall cancer treatment outcomes elsewhere.<\/p>\n

For patients, the improved survival outcomes may be the headline figure, but they are not the whole story, said\u00a0Vaitkevi\u010dien\u0117.<\/p>\n

\u201cWe are not just talking about treatment, but also quality of life. Not only after, but also during the treatment,\u201d she said. Up to 70% of children undergoing chemotherapy are affected by at least one severe side-effect, including serious infections, acute or long-term organ damage, thrombosis and metabolic disorders.<\/p>\n

Sharing data can help doctors avoid complications for their patients and reassure them while they are being treated. It also boosted the confidence of the doctors working at the hospital.<\/p>\n

\u201cYou can talk to the patients slightly differently,\u201d said\u00a0Vaitkevi\u010dien.<\/p>\n

\u201cYou\u2019re more confident when you can say this is not our treatment plan alone, children in other countries are treated in the same way,\u201c she said. \u201cAll this adds to their quality of life.\u201c<\/p>\n

Research in this article was funded by the EU\u2019s Horizon Programme. The views of the interviewees don\u2019t necessarily reflect those of the European Commission. <\/em><\/p>\n

More info:<\/p>\n